WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (www.dicerna.com), a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™, announced today the appointment of C. Ronald Kahn, M.D. to its Scientific Advisory Board (SAB). Dr. Kahn is a distinguished scientific expert in diabetes and obesity and has pioneered research in insulin signaling and insulin resistance.
